Category: Announcements
-
RougeTx Launches with HHT as Lead Therapeutic Program
RougeTx, a new biotechnology company focused on vascular disease, has launched with $58 million in Series A financing to advance RTX-001, an investigational treatment…
-
Tectonic Reports Early Safety Data for TX2100: What It Means for HHT Research
The hereditary hemorrhagic telangiectasia (HHT) treatment landscape continues to grow. On September 29, Tectonic Therapeutic announced early clinical results for TX2100, an investigational therapy…